Physician profile
Yi Feng
NPI 1639179229
$53,678.20
in general payments reported to CMS, 2019-2025
81 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,415 · 2020: $5,841 · 2021: $5,288 · 2022: $5,317 · 2023: $8,473 · 2024: $7,107 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $13K · Travel and Lodging: $413 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,481.85 |
| Consulting Fee | $12,523.00 |
| Travel and Lodging | $413.27 |
| Education | $399.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,012.38 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $5,585.17 | 2019-2025 | Erleada, Akeega, Balversa |
| Incyte Corporation | $4,752.81 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $3,035.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,678.45 | 2019-2025 | Opdivo, Opdualag, Onureg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,915.27 | 2019-2025 | Gilotrif |
| Amgen INC. | $1,854.36 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Genzyme Corporation | $1,791.60 | 2019-2025 | |
| Celgene Corporation | $1,707.87 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Merck Sharp & Dohme LLC | $1,683.23 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Beigene USA, INC. | $1,585.01 | 2020-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $1,395.97 | 2019-2025 | |
| Pfizer INC. | $1,310.78 | 2019-2025 | |
| Genentech USA, INC. | $1,204.62 | 2019-2025 | Tecentriq, Perjeta, Phesgo |
| Seagen INC. | $1,026.90 | 2019-2025 | Adcetris, Tukysa, Padcev |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $956.10 | 2019-2025 | |
| Astellas Pharma US INC | $928.36 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Glaxosmithkline, LLC. | $770.85 | 2020-2025 | Ojjaara, Jemperli, Blenrep |
| Daiichi Sankyo INC. | $630.17 | 2019-2025 | Enhertu, Injectafer |
| Emd Serono, INC. | $611.82 | 2019-2024 | |
| Gilead Sciences, INC. | $547.15 | 2019-2025 | Trodelvy |
| Beigene, LTD. | $525.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $511.90 | 2019-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $466.43 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Karyopharm Therapeutics INC. | $446.50 | 2020-2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $390.48 | 2019-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $358.58 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $324.27 | 2019-2025 | Libtayo, Lynozyfic |
| Array Biopharma INC | $306.25 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $278.56 | 2019-2025 | Onivyde |
| Exelixis INC. | $270.04 | 2019-2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $246.86 | 2020-2024 | Rezlidhia, Tavalisse |
| Kite Pharma, INC. | $219.47 | 2020-2025 | Yescarta |
| Beone Medicines USA, INC. | $212.28 | 2025 | Tevimbra, Brukinsa |
| Epizyme, INC. | $208.48 | 2020-2022 | |
| Iovance Biotherapeutics, INC. | $191.02 | 2024-2025 | Amtagvi |
| Mirati Therapeutics, INC. | $185.72 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $174.16 | 2022-2025 | |
| Lilly USA, LLC | $174.16 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Myriad Genetic Laboratories, INC. | $161.99 | 2021-2025 | Precisetumor, Myrisk |
| Aveo Pharmaceuticals, INC. | $128.14 | 2022-2024 | Fotivda |
| Springworks Therapeutics, INC. | $127.06 | 2024-2025 | Ogsiveo |
| Puma Biotechnology, INC. | $123.86 | 2020-2025 | |
| Tesaro, INC. | $116.04 | 2019 | |
| Sobi, INC | $115.91 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $112.88 | 2021-2025 | Qinlock, Romvimza |
| Tempus Ai, INC | $92.95 | 2025 | Xt Cdx |
| Kyowa Kirin, INC. | $92.83 | 2019-2023 | Poteligeo |
| Morphosys, US INC. | $73.20 | 2022-2023 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $72.43 | 2020-2025 | Monoferric |
| Agios Pharmaceuticals, INC. | $67.83 | 2019-2022 | |
| Caris Mpi, INC. | $66.18 | 2025 | Mi Cancer Seek |
| Teva Pharmaceuticals USA, INC. | $60.95 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $59.04 | 2022-2024 | |
| Adc Therapeutics America, INC. | $58.89 | 2022-2025 | |
| Clovis Oncology, INC. | $58.24 | 2019-2021 | |
| Taiho Oncology, INC. | $55.32 | 2019-2021 | |
| Genmab U.S., INC. | $50.33 | 2023-2025 | Epkinly |
| Janssen Pharmaceuticals, INC | $45.88 | 2019-2020 | |
| Organon LLC | $38.04 | 2022-2023 | |
| Secura Bio, INC. | $35.83 | 2020-2022 | |
| Tersera Therapeutics LLC | $34.72 | 2020-2021 | |
| Pharmaessentia USA Corporation | $33.77 | 2024 | Besremi |
| Myovant Sciences INC. | $28.65 | 2022 | |
| Biocompatibles, INC. | $24.88 | 2019 | |
| Tg Therapeutics, INC. | $24.15 | 2022 | |
| Coherus Oncology, INC. | $22.62 | 2023 | |
| Azurity Pharmaceuticals, INC. | $21.08 | 2025 | Vivimusta, Danziten |
| Otsuka America Pharmaceutical, INC. | $19.08 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.57 | 2019 | |
| Apellis Pharmaceuticals, INC. | $18.26 | 2022 | |
| Dova Pharmaceuticals | $16.47 | 2021 | |
| Stemline Therapeutics INC. | $16.19 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.51 | 2024 | |
| Verastem, INC. | $15.14 | 2019 | |
| Innate Pharma, INC | $14.79 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $13.84 | 2020 | |
| Mylan Institutional INC. | $13.68 | 2020 | |
| Foundation Medicine, INC. | $13.17 | 2020 | |
| Heron Therapeutics, INC. | $13.16 | 2021 | |
| Alnylam Pharmaceuticals INC. | $11.92 | 2020 |
Drugs and devices associated with these payments
Imfinzi $3,023Tagrisso $1,802Keytruda $869Opdivo $753Reblozyl $680Pomalyst $545Enhertu $485Sarclisa $426Imbruvica $397Brukinsa $392Erleada $387Jakafi $357Adcetris $352Trodelvy $309Kisqali $302Padcev $294Xtandi $283Ojjaara $280Krazati $257Braftovi $240Mektovi $240Tukysa $236Venclexta $235Akeega $231Ultomiris $226Lenvima $226Talzenna $221Fabhalta $213Lorbrena $199Ninlaro $198Xpovio $197Amtagvi $191Balversa $190Monjuvi $188Elrexfio $181Opdualag $173Rezlidhia $166Tavalisse $166Onivyde $165Rybrevant $164Scemblix $154Tecentriq $154Perjeta $149Phesgo $149Orgovyx $148Ibrance $147Yescarta $145Lynparza $142Welireg $137Zepzelca $135Onureg $134Tevimbra $134Jemperli $128Ogsiveo $127Tecvayli $126Breyanzi $122Cablivi $121Epkinly $119Libtayo $119Cabometyx $115Inlyta $110Xalkori $109Xt Cdx $92.95Paxlovid $92.40Nubeqa $90.65Precisetumor $88.86Pluvicto $88.72Zynyz $88.59Enjaymo $86.11Injectafer $85.81Itovebi $82.98Vonjo $82.18Polivy $79.79Lunsumio $79.79Poteligeo $77.51Fotivda $74.34Eliquis $74.30Gilotrif $74.25Lumakras $72.38Mi Cancer Seek $66.18Qinlock $63.60Darzalex $62.69Elitek $61.69Vitrakvi $58.55Stivarga $58.55Lutathera $50.96Xofigo $49.10Mekinist $46.97Vyloy $44.49Lynozyfic $44.32Romvimza $43.98Bosulif $43.85Carvykti $43.71Ayvakit $43.59Talvey $40.85Tibsovo $38.35Columvi $36.32Comirnaty $33.82Promacta $33.80Besremi $33.77
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Feng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.